Mechanistic oncology research points to RNA modification as both a driver of tumor survival and a potential lever for therapy. A study found that the m6A reader protein YTHDF2 promotes melanoma progression by destabilizing HMOX1 mRNA and shielding tumor cells from ferroptosis; the paper also suggests metformin may be able to exploit the vulnerability.